LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

Search

Emergent BioSolutions Inc

Fermé

SecteurSoins de santé

10.76 -3.58

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.72

Max

11.25

Chiffres clés

By Trading Economics

Revenu

63M

51M

Ventes

90M

231M

P/E

Moyenne du Secteur

8.189

79.874

Marge bénéficiaire

22.155

Employés

900

EBITDA

95M

96M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+34.29% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

57M

577M

Ouverture précédente

14.34

Clôture précédente

10.76

Score Technique

By Trading Central

Confiance

Bullish Evidence

Emergent BioSolutions Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 déc. 2025, 21:16 UTC

Acquisitions, Fusions, Rachats

Marsh McLennan Agency Acquires Three Hawaii-Based Insurance Brokerages

1 déc. 2025, 18:51 UTC

Principaux Mouvements du Marché

Shopify Stock Falls on Cyber Monday System Outages

1 déc. 2025, 23:47 UTC

Market Talk

Nikkei May Rise on Bargain Hunting -- Market Talk

1 déc. 2025, 23:27 UTC

Acquisitions, Fusions, Rachats

Genting Bhd. Stake in Genting Malaysia Now at 73.13% Vs. 49.36% Ahead of Take Private Offer Made in October

1 déc. 2025, 23:26 UTC

Acquisitions, Fusions, Rachats

Genting Bhd.: Offer to Take Genting Malaysia Private Closed on Dec.1

1 déc. 2025, 23:25 UTC

Acquisitions, Fusions, Rachats

Bitcoin Rout Picks Up Steam as Investors Fret Over a New 'Crypto Winter' -- WSJ

1 déc. 2025, 21:52 UTC

Acquisitions, Fusions, Rachats

Wood Partners Announces Itochu Corp. Purchase of 19.5% of Wood Partners

1 déc. 2025, 21:42 UTC

Acquisitions, Fusions, Rachats

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

1 déc. 2025, 21:41 UTC

Market Talk

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1 déc. 2025, 21:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 déc. 2025, 21:41 UTC

Market Talk

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1 déc. 2025, 21:17 UTC

Acquisitions, Fusions, Rachats

Commercial Metals Expects to Close Foley Products Deal by End of 2025 >CMC

1 déc. 2025, 21:17 UTC

Acquisitions, Fusions, Rachats

Commercial Metals Completes Acquisition of Concrete Pipe & Precast for $675M Cash >CMC

1 déc. 2025, 21:15 UTC

Acquisitions, Fusions, Rachats

Commercial Metals Completes Acquisition Of Concrete Pipe & Precast, LLC >CMC

1 déc. 2025, 20:15 UTC

Market Talk

Natural Gas Turns Positive Amid Mixed Weather Trends -- Market Talk

1 déc. 2025, 20:00 UTC

Acquisitions, Fusions, Rachats

Marsh McLennan Agency Acquires Three Hawai'i-based Insurance Brokerages >MMC

1 déc. 2025, 18:54 UTC

Market Talk

Silver Hits New Record As Momentum Continues -- Market Talk

1 déc. 2025, 18:46 UTC

Market Talk

Luxury Seen With Accelerating Growth Next Year -- Market Talk

1 déc. 2025, 16:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 déc. 2025, 16:41 UTC

Market Talk

Rapid Wage Growth in Canada to Keep BOC Sidelined -- Market Talk

1 déc. 2025, 16:20 UTC

Market Talk

Yen Could Strengthen Further Against Dollar on Rate-Hike Prospects -- Market Talk

1 déc. 2025, 16:00 UTC

Résultats

Strategy Helped Solve Its Bitcoin-Preferred Problem. Here's How. -- Barrons.com

1 déc. 2025, 15:51 UTC

Acquisitions, Fusions, Rachats

Goldman Makes a $2 Billion Bet on 'Boomer Candy' -- WSJ

1 déc. 2025, 15:47 UTC

Market Talk

Global Equities Roundup: Market Talk

1 déc. 2025, 15:47 UTC

Market Talk

Airbus Guidance Is at Risk -- Market Talk

1 déc. 2025, 15:46 UTC

Acquisitions, Fusions, Rachats

Synopsys Gets a New Investor. What to Know About Nvidia's Stake. -- Barrons.com

1 déc. 2025, 15:33 UTC

Market Talk

Airbus Selloff May Be Overdone -- Market Talk

1 déc. 2025, 15:26 UTC

Market Talk

Warming Forecast Pressures Natural Gas -- Market Talk

1 déc. 2025, 15:23 UTC

Market Talk

Geopolitical Turmoil Supports Crude Oil -- Market Talk

1 déc. 2025, 14:59 UTC

Acquisitions, Fusions, Rachats

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

Comparaison

Variation de prix

Emergent BioSolutions Inc prévision

Objectif de Prix

By TipRanks

34.29% hausse

Prévisions sur 12 Mois

Moyen 15 USD  34.29%

Haut 15 USD

Bas 15 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

4.95 / N/ASupport & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat